Trastuzumab Deruxtecan

Extended indication	Patients With HER2-Expressing Solid Tumors.
Therapeutic value	No estimate possible yet
Registration phase	Clinical trials

Product

Active substance	Trastuzumab Deruxtecan
Domain	Oncology
Reason of inclusion	Indication extension
Main indication	Tumour agnostic medication
Extended indication	Patients With HER2-Expressing Solid Tumors.
Proprietary name	Enhertu
Manufacturer	AstraZeneca
Route of administration	Intravenous
Therapeutical formulation	Intravenous drip
Budgetting framework	Intermural (MSZ)
Additional remarks	Trastuzumab deruxtecan (T-DXd) is a human epidermal growth factor 2 (HER2)-directed antibody-drug conjugate approved in HER2-expressing breast and gastric cancers and HER2-mutant non-small-cell lung cancer.

Therapeutic value	No estimate possible yet
Frequency of administration	1 times every 3 weeks
Dosage per administration	5.4 mg/kg
References	NCT04482309

There is currently nothing known about the expected patient volume.

Cost	125,143.00
References	CBS; fabrikant
Additional remarks	Trastuzumab-deruxtecan is beschikbaar in flacons van 100mg. De apotheekinkoopprijs (AIP) bedraag €1.800 per flacon. De aanbevolen dosering is 5,4mg per kg per behandelcyclus van 21 dagen. Op basis van een gemiddeld gewicht van 72kg bedragen de kosten van trastuzumab-deruxtecan €7.200 per behandelcyclus (4 flacons van €1.800). De kosten per maand zijn dan €10.428,57 ((365/12)*(7.200/21)). De kosten per patiënt per jaar zijn dan €125.143.

There is currently nothing known about the possible total cost.

There is currently nothing known about off label use.

There is currently nothing known about indication extensions.

There is currently no futher information available.